

Publications

Clinical Trials:

[Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.](#)

Weiss, B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, and Fisher MJ. *Pediatric Blood and Cancer*. 2014 Jun;61(6):982-986.

[Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.](#)

Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, and Packer RJ. *Pediatric Blood and Cancer*. 2014 Sep;61(9):1598-602.

[Phase 2 randomized flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.](#)

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, and Balis FM. *Neuro Oncol*. 2014 May;16(5):707-18.

[A phase 2 study of pegylated interferon alpha-2b \(PEG-Intron®\) in children with diffuse intrinsic pontine glioma.](#)

Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, Shih J, and Camphausen K. *Cancer*. 2012 Jul 15;118(14):3607-13.

[Very high-dose methotrexate \(33.6 g/m²\) as CNS preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P, and CCG-144P.](#)

Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, and Bleyer WA. *Leukemia & Lymphoma*. 2006 47(12):2488-2504.

Cognitive/Neurobehavioral Functioning:

[Neurobehavioral profiles in individuals with Hyperimmunoglobulin E Syndrome \(HIES\) and brain white matter hyperintensities.](#)

Martin S, Wolters P, Billings N, Toledo-Tamula MA, Hammoud DA, Welch P, Darnell D, Holland SM, and Freeman AF. *J Clin Immunol*. 2013 Oct;33(7):1175-84.

[Neurodevelopment of children under 3 years of age with Smith-Magenis syndrome.](#)

Wolters PL, Gropman AL, Martin SC, Smith MR, Hildenbrand HL, Brewer CC, and Smith AC. *Pediatr Neurol.* 2009 Oct;41(4):250-8.

[Neuropsychological testing and biomarkers in the management of brain metastases.](#)

Baschnagel A, Wolters PL, and Camphausen K. *Radiat Oncol.* 2008 Sep 17;3:26.

[Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.](#)

Steffen-Smith EA, Wolters PL, Albert PS, Baker EH, Shimoda KC, Barnett AS, and Warren KE. *Childs Nerv Syst.* 2008 Jul;24(7):807-13. Epub 2008 Feb 22.

[Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy \(HAART\).](#)

Martin SC, Wolters PL, Toledo-Tamula MA, Zeichner SL, Hazra R, and Civitello L. *Dev Neuropsychol.* 2006;30(2):633-57.

Social-Emotional Functioning/Quality of Life:

[Attitudes about internet support groups among adolescents and young adults with neurofibromatosis type 1 and their parents.](#)

Martin S, Wolters PL, Baldwin A, Roderick MC, Toledo-Tamula MA, Gillespie A, and Widemann B. *J Genet Couns.* 2014 Oct; 23(5):796-804.

[Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.](#)

Wolters PL, Martin S, Merker VL, Gardner KL, Hingtgen CM, Tonsgrad JH, Schorry EK, and Baldwin A; REiNS International Collaboration. *Neurology.* 2013 Nov19;81(21 Suppl 1):S6-14.

[Family functioning and coping styles in families of children with cancer and HIV disease.](#)

Martin S, Calabrese SK, Wolters PL, Walker KA, Warren K, and Hazra R. *Clin Pediatr (Phila).* 2012 Jan;51(1):58-64.

[Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables.](#)

Martin S, Wolters P, Baldwin A, Gillespie A, Dombi E, Walker K, and Widemann BJ. *Pediatr Psychol.* 2012 Aug;37(7):713-24.

[Stressful life events and their relationship to psychological and medical functioning in children and adolescents with HIV infection.](#)

Elliott-DeSorbo DK, Martin S, and Wolters PL. *J Acquir Immune Defic Syndr.* 2009 Nov 1;52(3):364-70.

Medication Adherence:

[Pediatric psychologist use of adherence assessments and interventions.](#)

Wu YP, Rohan JM, Martin S, Hommel K, Greenley RN, Loiselle K, Ambrosino J, and Fredericks EM. *J Pediatr Psychol*. 2013 Jul;38(6):595-604.

[A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers.](#)

Martin S, Elliott-DeSorbo DK, Calabrese S, Wolters PL, Roby G, Brennan T, and Wood LV. *AIDS Patient Care STDS*. 2009 Aug;23(8):593-601.

[Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents.](#)

Calabrese SK, Martin S, Wolters PL, Toledo-Tamula MA, Brennan TL, and Wood LV. *AIDS Care*. 2012 July;24(9):1092-1096.